atorvastatin has been researched along with ag-490 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Fan, H; Liu, Z; Luo, W; Ouyang, F; Tang, L; Yan, Y; Yang, H; Yuan, W | 1 |
1 trial(s) available for atorvastatin and ag-490
| Article | Year |
|---|---|
Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
Topics: Aged; Amlodipine; Animals; Atorvastatin; Essential Hypertension; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinases; Rats; Rats, Inbred SHR; Signal Transduction; STAT Transcription Factors | 2023 |
1 other study(ies) available for atorvastatin and ag-490
| Article | Year |
|---|---|
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Atorvastatin; Cyclooxygenase 2; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptides; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tyrphostins; Up-Regulation | 2008 |